China
China Allogeneic Cell Therapy Market Industry Trends and Forecast to 2034: Segmented by (Cell Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
China · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
China (this report) at $102.7 Mn.
India at 28% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$737.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $81.3 Mn | — | — |
| 2025 (base) | $102.7 Mn | +$21.4 Mn | — |
| 2026 (forecast) | $129.7 Mn | +$27.0 Mn | +26.3% |
| 2027 (forecast) | $163.9 Mn | +$34.1 Mn | +59.5% |
| 2028 (forecast) | $207.0 Mn | +$43.1 Mn | +101.5% |
| 2029 (forecast) | $261.4 Mn | +$54.4 Mn | +154.5% |
| 2030 (forecast) | $330.1 Mn | +$68.7 Mn | +221.4% |
| 2031 (forecast) | $417.0 Mn | +$86.8 Mn | +305.9% |
| 2032 (forecast) | $526.6 Mn | +$109.7 Mn | +412.7% |
| 2033 (forecast) | $665.1 Mn | +$138.5 Mn | +547.5% |
| 2034 (forecast) | $840.1 Mn | +$174.9 Mn | +717.8% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$629.0 Mn
China (this report)
$102.7 Mn
Canada
$98.3 Mn
Japan
$80.4 Mn
Germany
$55.9 Mn
France
$39.7 Mn
Italy
$33.5 Mn
UK
$30.3 Mn
Spain
$30.2 Mn
Brazil
$30.7 Mn
India
$30.6 Mn
Ecuador
$28.9 Mn
Mexico
$22.7 Mn
Saudi Arabia
$23.0 Mn
Australia
$19.3 Mn
New Zealand
$16.5 Mn
Russia
$13.1 Mn
South Africa
$8.3 Mn
UAE
$7.8 Mn
Egypt
$4.3 Mn
Philippines
$3.0 Mn
Hong Kong
$2.4 Mn
Malaysia
$2.0 Mn
Thailand
$1.7 Mn
Singapore
$1.6 Mn
Kenya
$1.1 Mn
Allogeneic cell therapies use cells from healthy donors to make ready-to-use treatments that do not have to be made for each patient.
Key segments of the allogeneic Cell Therapy market include cell type (T Cells, NK Cells and Stem Cells) and indication (Oncology, Autoimmune and Regenerative Medicine).
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the allogeneic Cell Therapy market.
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the allogeneic Cell Therapy market.
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the allogeneic Cell Therapy market. Payers are still working out how to pay for one-time cures.
The allogeneic Cell Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for allogeneic Cell Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.
What doctors and scientists are doing in Allogeneic Cell Therapy right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
China · 3 shared keywords
China · 2 shared keywords
China · 2 shared keywords
China · 1 shared keyword
China · 1 shared keyword
China · 1 shared keyword
Medical Devices · China
Healthcare Services · China
Healthcare Services · China
Healthcare Services · China
Healthcare Services · China
Healthcare Services · China